Employing a mouse model of IDH-mutant glioma, the authors demonstrated that selective inhibition of mutant IDH suppresses 2-HG production, restoring T-cell immunity and enhancing the anti-tumor effect of immune checkpoint inhibitor. This evidence concerns the gene IDH1 and central nervous system cancer.